ARID1B and bladder transitional cell carcinoma: Additionally, high levels of ARID1B expression have been linked to poor clinical outcomes in bladder urothelial carcinoma and breast carcinoma, while low ARID1A levels have been linked to poor clinical outcomes13–17.